Published in Breast Cancer Res on January 01, 2007
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86
TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 4.92
Mutant p53: one name, many proteins. Genes Dev (2012) 4.33
Regularized Multivariate Regression for Identifying Master Predictors with Application to Integrative Genomics Study of Breast Cancer. Ann Appl Stat (2010) 3.94
Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res (2008) 3.45
Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med (2010) 3.43
miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One (2011) 2.70
Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest (2011) 1.99
Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc Natl Acad Sci U S A (2010) 1.78
Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol (2010) 1.64
Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol (2011) 1.59
p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome. Genes Cancer (2011) 1.54
Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev (2008) 1.53
Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med (2012) 1.43
Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol (2010) 1.43
Topology based data analysis identifies a subgroup of breast cancers with a unique mutational profile and excellent survival. Proc Natl Acad Sci U S A (2011) 1.40
Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol (2010) 1.24
Patient-specific data fusion defines prognostic cancer subtypes. PLoS Comput Biol (2011) 1.16
CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer. Mol Oncol (2008) 1.16
Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res (2008) 1.15
Combining gene signatures improves prediction of breast cancer survival. PLoS One (2011) 1.11
Invasive Breast Cancer: Recognition of Molecular Subtypes. Breast Care (Basel) (2011) 1.09
Defining the ATM-mediated barrier to tumorigenesis in somatic mammary cells following ErbB2 activation. Proc Natl Acad Sci U S A (2010) 1.09
hCLCA2 Is a p53-Inducible Inhibitor of Breast Cancer Cell Proliferation. Cancer Res (2009) 1.08
Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation. Mol Cancer Res (2010) 1.07
Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women. PLoS One (2013) 1.07
NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations. Mol Cancer (2010) 1.06
MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. Expert Rev Mol Diagn (2009) 1.02
Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer (2011) 1.01
Epithelial-stromal interaction 1 (EPSTI1) substitutes for peritumoral fibroblasts in the tumor microenvironment. Am J Pathol (2010) 1.01
Gene expression analyses in breast cancer epidemiology: the Norwegian Women and Cancer postgenome cohort study. Breast Cancer Res (2008) 0.99
Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. Breast Cancer Res (2012) 0.98
Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev (2015) 0.96
Triple negative breast carcinoma is a prognostic factor in Taiwanese women. BMC Cancer (2009) 0.96
BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. BMC Cancer (2010) 0.95
TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients. Breast Cancer Res (2014) 0.94
Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. Curr Genomics (2008) 0.92
Divide and conquer: the genetic basis of molecular subclassification of breast cancer. EMBO Mol Med (2011) 0.91
Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity. Cell Cycle (2012) 0.91
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res (2012) 0.90
PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing. PLoS One (2014) 0.89
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. Nat Commun (2016) 0.88
Integrative functional genomics analysis of sustained polyploidy phenotypes in breast cancer cells identifies an oncogenic profile for GINS2. Neoplasia (2010) 0.88
miR-661 downregulates both Mdm2 and Mdm4 to activate p53. Cell Death Differ (2013) 0.88
BST-2/tetherin is overexpressed in mammary gland and tumor tissues in MMTV-induced mammary cancer. Virology (2013) 0.87
Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell (2014) 0.87
Identification of potential synthetic lethal genes to p53 using a computational biology approach. BMC Med Genomics (2013) 0.87
P16 and p53 play distinct roles in different subtypes of breast cancer. PLoS One (2013) 0.86
A signature-based method for indexing cell cycle phase distribution from microarray profiles. BMC Genomics (2009) 0.86
Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status. BMC Cancer (2014) 0.85
Up-regulation of kin17 is essential for proliferation of breast cancer. PLoS One (2011) 0.84
Ovarian cancer biomarker discovery based on genomic approaches. J Cancer Prev (2013) 0.84
TP53 mutation, epithelial-mesenchymal transition, and stemlike features in breast cancer subtypes. J Biomed Biotechnol (2012) 0.84
Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. J Cancer Res Clin Oncol (2010) 0.83
Regulation of cancer stem cells by p53. Breast Cancer Res (2008) 0.83
p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab. Oncotarget (2014) 0.82
Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer. Carcinogenesis (2011) 0.82
Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression. Oncotarget (2015) 0.82
High incidence of microsatellite instability and loss of heterozygosity in three loci in breast cancer patients receiving chemotherapy: a prospective study. BMC Cancer (2012) 0.81
AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma. Virchows Arch (2012) 0.80
Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients. Fam Cancer (2012) 0.80
Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 status. Carcinogenesis (2014) 0.80
Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway. Br J Cancer (2012) 0.79
p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer. Breast Cancer Res (2016) 0.79
Cancer Stem and Progenitor-Like Cells as Pharmacological Targets in Breast Cancer Treatment. Breast Cancer (Auckl) (2015) 0.78
Gene Expression Profiling of Breast Cancer Brain Metastasis. Sci Rep (2016) 0.78
Nuclear CSPP1 expression defined subtypes of basal-like breast cancer. Br J Cancer (2014) 0.78
Systematical detection of significant genes in microarray data by incorporating gene interaction relationship in biological systems. PLoS One (2010) 0.78
A Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to Tumorigenesis. Int J Mol Sci (2016) 0.78
The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer. Pharmaceutics (2013) 0.78
The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer. PLoS One (2015) 0.78
Prevalence of germline TP53 mutations in HER2+ breast cancer patients. Breast Cancer Res Treat (2013) 0.77
miRNome of inflammatory breast cancer. BMC Res Notes (2014) 0.77
Reinventing diagnostics for personalized therapy in oncology. Cancers (Basel) (2010) 0.77
Racial disparity in metabolic regulation of cancer. Front Biosci (Landmark Ed) (2017) 0.76
TP53 genetic alterations in Arab breast cancer patients: Novel mutations, pattern and distribution. Oncol Lett (2011) 0.76
MDM2 expression and regulation in prostate cancer racial disparity. Int J Clin Exp Pathol (2008) 0.76
The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells - A data description. Genom Data (2014) 0.76
Application of pharmacologically induced transcriptomic profiles to interrogate PI3K-Akt-mTOR pathway activity associated with cancer patient prognosis. Oncotarget (2016) 0.76
p16 expression correlates with basal-like triple-negative breast carcinoma. Ecancermedicalscience (2013) 0.75
Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer. Oncogenesis (2016) 0.75
DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival. Oncotarget (2016) 0.75
Inherited and acquired alterations in development of breast cancer. Appl Clin Genet (2011) 0.75
Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients. Oncoscience (2015) 0.75
Multimodal hazard rate for relapse in breast cancer: quality of data and calibration of computer simulation. Cancers (Basel) (2014) 0.75
Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nat Commun (2016) 0.75
PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells. J Pathol Clin Res (2017) 0.75
MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells. Cell Death Dis (2017) 0.75
Adiposity is associated with p53 gene mutations in breast cancer. Breast Cancer Res Treat (2015) 0.75
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
p53 mutations in human cancers. Science (1991) 31.96
Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A (1971) 31.05
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A (2001) 13.30
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
Outcome signature genes in breast cancer: is there a unique set? Bioinformatics (2004) 7.96
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res (2001) 6.78
The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat (1992) 6.51
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res (2000) 4.66
Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell (2004) 3.73
TP53 and breast cancer. Hum Mutat (2003) 2.75
Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis. BMC Genomics (2002) 2.42
Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer (1999) 2.36
Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet (2000) 2.15
TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol (2003) 1.91
Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes Chromosomes Cancer (1992) 1.77
Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. Proc Natl Acad Sci U S A (1991) 1.22
Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA. Cancer Genet Cytogenet (2001) 1.05
Polymerase chain reaction detection of a highly polymorphic VNTR segment in intron 1 of the human p53 gene. Clin Chem (1993) 0.98
Double-peaked time distribution of mortality for breast cancer patients undergoing mastectomy. Breast Cancer Res Treat (2002) 0.98
Management of primary breast cancer: an update. Onkologie (2004) 0.93
Mutation screening of the TP53 gene by temporal temperature gradient gel electrophoresis. Methods Mol Biol (2005) 0.93
Interpreting and integrating risk factors for patients with primary breast cancer. J Natl Cancer Inst Monogr (2001) 0.91
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Signatures of mutational processes in human cancer. Nature (2013) 21.63
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
International network of cancer genome projects. Nature (2010) 20.35
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature (2005) 18.30
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A (2002) 12.68
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
The life history of 21 breast cancers. Cell (2012) 10.59
Lysyl oxidase is essential for hypoxia-induced metastasis. Nature (2006) 8.28
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med (2006) 6.04
Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet (2011) 5.62
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer (2006) 5.39
Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res (2006) 4.25
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol (2012) 3.95
Mutation of GATA3 in human breast tumors. Oncogene (2004) 3.92
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer (2010) 3.78
Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One (2012) 3.74
Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell (2004) 3.73
Morphologic reappraisal of serrated colorectal polyps. Am J Surg Pathol (2003) 3.59
Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer (2005) 3.26
Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A (2009) 3.19
A streamlined platform for high-content functional proteomics of primary human specimens. Nat Methods (2005) 3.00
Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics (2006) 2.86
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One (2011) 2.70
CGH-Explorer: a program for analysis of array-CGH data. Bioinformatics (2004) 2.65
Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis. BMC Genomics (2002) 2.42
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci Transl Med (2013) 2.34
Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat (2011) 2.23
EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. Sci Signal (2010) 2.16
Wobble-enhanced ARMS method for detection of KRAS and BRAF mutations. Diagn Mol Pathol (2011) 2.12
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol (2007) 2.06
p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol (2008) 2.04
Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study. Breast Cancer Res (2004) 2.03
Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res (2004) 2.01
Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res (2005) 2.00
Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology (2009) 1.91
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res (2003) 1.89
EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol (2002) 1.86
Discovery and validation of breast cancer subtypes. BMC Genomics (2006) 1.83
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A (2011) 1.78
Copynumber: Efficient algorithms for single- and multi-track copy number segmentation. BMC Genomics (2012) 1.74
RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis (2006) 1.70
Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res (2004) 1.67
Gene expression profiling of peripheral blood cells for early detection of breast cancer. Breast Cancer Res (2010) 1.64
Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther (2006) 1.64
Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol (2010) 1.63
PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat (2005) 1.61
Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol (2011) 1.59
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res (2005) 1.59
Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet (2009) 1.58
Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing. PLoS One (2012) 1.58
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One (2011) 1.57
Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients. Genes Chromosomes Cancer (2008) 1.54
Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. Cancer Res (2005) 1.52
Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer (2010) 1.46
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol (2010) 1.45
New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer (2008) 1.45
RNA extraction from ten year old formalin-fixed paraffin-embedded breast cancer samples: a comparison of column purification and magnetic bead-based technologies. BMC Mol Biol (2007) 1.45
Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol (2010) 1.44
DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer (2007) 1.44
Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene (2004) 1.42
Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res (2009) 1.41
Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol Oncol Res (2004) 1.41
Merging transcriptomics and metabolomics--advances in breast cancer profiling. BMC Cancer (2010) 1.41
Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat (2010) 1.40
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell (2011) 1.40
Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet (2013) 1.39
CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression. Mod Pathol (2004) 1.38
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med (2013) 1.38
Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer (2006) 1.33
DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables. Mol Oncol (2010) 1.33
Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. Hum Mutat (2003) 1.33
Genomics in breast cancer-therapeutic implications. Nat Clin Pract Oncol (2005) 1.32
Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol (2013) 1.30
Genes harbouring susceptibility SNPs are differentially expressed in the breast cancer subtypes. Breast Cancer Res (2007) 1.30
CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol (2012) 1.29
Deciphering normal blood gene expression variation--The NOWAC postgenome study. PLoS Genet (2010) 1.29
11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat (2012) 1.26
Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. Clin Cancer Res (2003) 1.26